Life Sciences Partners (LSP)
LSP is a leading independent European investment firm, providing financing for private and public life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. With over 1 bn EUR of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s largest and most experienced specialist life-science investors.
LifeCare Partners (LCP)
LifeCare Partners is an independent investment firm providing financing to private and public life science companies. LifeCare Partners targets the entire life science industry with special focus on medical technology, diagnostics, biopharmaceuticals, food & nutrition, industrial biotechnology, biomaterials, e-health and bioenergy. Based in Basel, the LifeCare Partners team has successfully invested in more than 35 life science companies over the last years, of which a large number have already been listed on the stock exchange or have been acquired by leading players in the life science industry.
Bayern Kapital is based in Landshut, Germany, and was founded on the initiative of the Bavarian government in 1995. It is a wholly-owned subsidiary of the Bavarian LfA Förderbank. As the venture capital organization of Germany’s State of Bavaria, Bayern Kapital provides equity capital financing for the founders of young innovative technology companies in Bavaria. Presently, Bayern Kapital manages eleven investment funds with a total volume of around 340 Mio. EUR. So far, it has invested almost 227 Mio. EUR in 245 innovative companies in the fields of technology in various sectors including life science, software & IT, medical technology, materials and new materials, nanotechnology and environmental technology. This way, almost 5,000 long-term jobs in sustainable companies have been created in Bavaria.
High-Tech Gründerfonds invests in young, high potential high-tech start-ups. The seed financing provided is designed to enable start-ups to take an idea through prototyping and to market launch. Typically, High-Tech Gründerfonds invests 600,000 EUR in the seed stage, with the potential for up to a total of 2 Mio. EUR per portfolio company in follow-on financing. Investors in this public/private partnership include the Federal Ministry of Economics and Energy, the KfW Banking Group, as well as strategic corporate investors including ALTANA, BASF, Bayer, B. Braun, Robert Bosch, CEWE, Daimler, Deutsche Post DHL, Deutsche Telekom, Evonik, Lanxess, media + more venture Beteiligungs GmbH & Co. KG, METRO, Qiagen, RWE Innogy, SAP, Tengelmann and Carl Zeiss. High-Tech Gründerfonds has about 576 Mio. EUR under management in two funds (272 Mio. EUR HTGF I, 304 Mio. EUR HTGF II).
The IBG funds are based in Magdeburg, Germany, and are the venture capital funds of the federal state of Sachsen-Anhalt. The IBG funds provide equity capital financing for young innovative technology companies with long-term and above-average growth potential that are headquartered in or have a branch office in Sachsen-Anhalt. The IBG funds have already invested in over 100 companies since 1996. Currently approximately 50 companies are part of the portfolio. The IBG funds are managed by bmp Beteiligungsmanagement AG, Berlin and Magdeburg.
Omega Funds is a leading venture capital and growth equity investor within the broad life sciences sector. Founded in 2004, the firm is based in Boston, USA, and has a strategic relationship with NeoMed Management, a Jersey headquartered investment firm, which broadens its capabilities in Europe.
FUND+ is an open-ended Fund for long-term equity investment in innovative life sciences companies with a focus on Belgium. The objective is to create sustainable shareholders value, contribute to the development of a leadership position in the Life Sciences sector for Belgium and generate a tangible, beneficial societal impact.